مرکز منطقه ای اطلاع رساني علوم و فناوري - The evaluation of JAK2V617F mutation and thromboembolism in chronic myeloproliferative neoplasia patients; a single center experience

Abstract :

Purpose: Myeloproliferative neoplasms are clonal diseases associated with hemostasis and thrombosis anomalies and can progress to acute leukemia. Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Idiopathic Myelofibrosis (IMF) are bcr-abl negative myeloproliferative neoplasms. Materials and methods: In this study, the researchers evaluated 128 bcr-abl negative CMPN patients, who were followed in Izmir Bozyaka Traning and Research Hospital, Department of Hematology, between 2008 and 2013. Their demographic features, laboratory results, the state of JAK2V617F mutation and previous treatments were investigated retrospectively. Results: Of the total 128 patients, 63 patients were female and 65 were male. The patients’ ages were between 23and 87. Median age was sixty five. 87 of patients were JAK2V617F positive. 41 patients were JAK2V617F negative. 37 of the 87 JAK2V617F positive patients (37/87) and 13of the 87 JAK2V617F negative patients (13/87) had thrombotic events. The fact that JAK2V617F mutation positive patients had more thrombotic events was considered clinically and statistically significant (p=0.003). The most commonly seen thrombotic event was coroner artery diseases (20/50). Conclusion: In conclusion, JAK2V617F gene mutation is an important finding for diagnosis and complications of CMPN patients.